Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Olympic Anti-Doping Measures Lead To Increased Inspections Of Chinese Drug Manufacturers And Pharmacies

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Seven departments of the Chinese government initiated a program Oct. 18 to increase inspections of pharmacies and drug manufacturers in an effort to remove performance-enhancing substances from the OTC market in advance of next year's Beijing Olympics, Chinese officials told PharmAsia News

You may also be interested in...

Chinese Pharmacies To Provide Product Warrants To Customers; New Rules For Selling ‘Doping’ Drugs

SHANGHAI - Retail drugstores in China will now have to give detailed product "warrants" to consumers purchasing drugs, China's State FDA said in a notice issued June 27

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts